NeuroTrials Research Revenue and Competitors

Atlanta, GA USA

Location

N/A

Total Funding

Research

Industry

Estimated Revenue & Valuation

  • NeuroTrials Research's estimated annual revenue is currently $2M per year.(i)
  • NeuroTrials Research's estimated revenue per employee is $71,400

Employee Data

  • NeuroTrials Research has 28 Employees.(i)
  • NeuroTrials Research grew their employee count by 8% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.1M18-18%N/AN/A
#2
$3.5M4313%N/AN/A
#3
$3.2M390%N/AN/A
#4
$3.5M43N/AN/AN/A
#5
$3.6M445%N/AN/A
#6
$2M288%N/AN/A
#7
$22.8M2032%N/AN/A
#8
$0.2M4N/AN/AN/A
#9
$3.1M389%N/AN/A
#10
$1M17-11%N/AN/A
Add Company

What Is NeuroTrials Research?

NeuroTrials Research, Inc. is a premier, independent, clinical research facility located in Atlanta, GA. Our spacious, state-of-the-art facility is conveniently located near three of North Atlanta’s major hospital systems and is in walking distance of rapid transit (MARTA). Thanks to NeuroTrials, people in our community with specific health concerns have the chance to participate in nationally-sponsored clinical trials right here at home. If you qualify, you may have access locally to medications and medical devices that are not yet available by prescription. Participating in clinical studies provides the opportunity to contribute to scientific efforts to find new and effective medical treatments. The nationally recognized physicians and researchers who founded NeuroTrials a decade ago attract clinical studies to Atlanta that have a profound impact on the health and welfare of both our community and the United States as a whole. All studies conducted at our site follow internationally accepted rules and regulations, regarding clinical research protocols.

keywords:N/A

N/A

Total Funding

28

Number of Employees

$2M

Revenue (est)

8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2M28-30%$12.7M
#2
$2.8M28N/AN/A
#3
$6.3M2812%N/A
#4
$4.9M280%N/A
#5
$4.1M28N/AN/A